Microparticles as vaccine delivery systems

Immunopotentiators in Modern Vaccines

Volumn , Issue , 2006, Pages 123-147

  O'Hagan, Derek ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748177116     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088403-2/50009-5     Document Type: Chapter

References (191)

1. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J. Control. Release 2002, 79:29-40.
2. Allaoui-Attarki K., Pecquet S., Fattal E., Trolle S., Chachaty E., Couvreur P., Andremont A. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(d,l-lactide-co-glycolide) microspheres. Infect. Immun. 1997, 65:853-857.
3. Alonso P.L., Sacarlal J., Aponte J.J., Leach A., Macete E., Milman J., Mandomando I., Spiessens B., Guinovart C., Espasa M., Bassat Q., Aide P., Ofori-Anyinam O., Navia M.M., Corachan S., Ceuppens M., Dubois M.C., Demoitie M.A., Dubovsky F., Menendez C., Tornieporth N., Ballou W.R., Thompson R., Cohen J. Efficacy of the Rts,S/As02a vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420.
4. Alving C.R. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta 1992, 1113:307-322.
5. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of Aids by a multiprotein DNA/Mva vaccine. Science 2001, 292:69-74.
6. Ando S., Putnam D., Pack D.W., Langer R. Plga microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J. Pharm. Sci. 1999, 88:126-130.
7. Bachmann M.F., Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 1997, 15:235-270.
8. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The Influence of antigen organization on B cell responsiveness. Science 1993, 262:1448-1451.
9. Barackman J.D., Ott G., Pine S., O'Hagan D.T. Oral administration of influenza vaccine in combination with the adjuvants Lt-K63 and Lt-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization. Clin. Diagn. Lab. Immunol. 2001, 8:652-657.
10. Baudner B.C., Balland O., Giuliani M.M., Von Hoegen P., Rappuoli R., Betbeder D., Del Giudice G. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic Ltk63 mutant delivered with nanoparticles. Infect. Immun. 2002, 70:4785-4790.
11. Baudner B.C., Giuliani M.M., Verhoef J.C., Rappuoli R., Junginger H.E., Giudice G.D. The concomitant use of the Ltk63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 2003, 21:3837-3844.
12. Bird A.P. CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 1987, 3:342-347.
13. Brayden D.J. Oral vaccination in man using antigens in particles: current status. Eur. J. Pharm. Sci. 2001, 14:183-189.
14. Briones M., Singh M., Ugozzoli M., Kazzaz J., Klakamp S., Ott G., O'Hagan D. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res. 2001, 18:709-711.
15. Cahill E.S., O'Hagan D.T., Illum L., Barnard A., Mills K.H., Redhead K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 1995, 13:455-462.
16. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandstrom E., Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998, 351:1320-1325.
17. Caputo A., Brocca-Cofano E., Castaldello A., De Michele R., Altavilla G., Marchisio M., Gavioli R., Rolen U., Chiarantini L., Cerasi A., Dominici S., Magnani M., Cafaro A., Sparnacci K., Laus M., Tondelli L., Ensoli B. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Vaccine 2004, 22:2910-2924.
18. Challacombe S.J., Rahman D., Jeffery H., Davis S.S., O'Hagan D.T. Enhanced secretory Iga and systemic Igg antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunol. 1992, 76:164-168.
19. Challacombe S.J., Rahman D., O'Hagan D.T. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine 1997, 15:169-175.
20. Cleland J.L., Barron L., Daugherty A., Eastman D., Kensil C., Lim A., Weissburg R.P., Wrin T., Vennari J., Powell M.F. Development of a single-shot subunit vaccine for HIV-1: 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant Mn Gp120. J. Pharm. Sci. 1997, 85:1350-1357.
21. Conway M.A., Madrigal-Estebas L., McClean S., Brayden D.J., Mills K.H. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 2001, 19:1940-1950.
22. Deng G.M., Tarkowski A. Synovial cytokine mrna expression during arthritis triggered by CpG motifs of bacterial DNA. Arthritis Res. 2001, 3:48-53.
23. Deng H., Wolff J.A. Self-amplifying expression from the T7 promoter in 3t3 mouse fibroblasts. Gene 1994, 143:245-249.
24. Deng H., Wang C., Acsadi G., Wolff J.A. High-efficiency protein synthesis from T7 RNA polymerase transcripts in 3t3 fibroblasts. Gene 1991, 109:193-201.
25. Denis-Mize K.S., Dupuis M., Singh M., Woo C., Ugozzoli D.T., Donnelly J.J., Ott G., McDonald D.M. Mechanisms of increased immunogenicity for DNA-based vaccines absorbed onto cationic microparticles. Cell Immunol. 2003, 225(1):12-20.
26. Denis-Mize K.S., Dupuis M., MacKichan M.L., Singh M., Doe B., O'Hagan D., Ulmer J.B., Donnelly J.J., McDonald D.M., Ott G. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 2000, 7:2105-2112.
27. Di Tommaso A., Saletti G., Pizza M., Rappuoli R., Dougan G., Abrignani S., Douce G., De Magistris M.T. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 1996, 64:974-979.
28. Dickinson B.L., Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 1995, 63:1617-1623.
29. Diwan M., Tafaghodi M., Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 2002, 85:247-262.
30. Douce G., Turcotte C., Cropley I., Roberts M., Pizza M., Domenghini M., Rappuoli R., Dougan G. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 1995, 92:1644-1648.
31. Douce G., Fontana M., Pizza M., Rappuoli R., Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 1997, 65:2821-2828.
32. Douce G., Giannelli V., Pizza M., Lewis D., Everest P., Rappuoli R., Dougan G. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants. Infect. Immun. 1999, 67:4400-4406.
33. Edelman R. New Generation Vaccines 1997, Vol. 2:173-192. Marcel Dekker, New York. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon (Eds.).
34. Egilmez N.K., Jong Y.S., Sabel M.S., Jacob J.S., Mathiowitz E., Bankert R.B. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000, 60:3832-3837.
35. Eldridge J.H., Hammond C.J., Meulbroek J.A., Staas J.K., Gilley R.M., Tice T.R. Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release 1990, 11:205-214.
36. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., Gilley R.M. Biodegradable and biocompatible poly(d,l-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 1991, 59:2978-2986.
37. Evans J.T., Ward J.R., Kern J., Johnson M.E. A single vaccination with protein-microspheres elicits a strong Cd8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4. Vaccine 2004, 22:1964-1972.
38. Evans R.K., Zhu D.M., Casimiro D.R., Nawrocki D.K., Mach H., Troutman R.D., Tang A., Wu S., Chin S., Ahn C., Isopi L.A., Williams D.M., Xu Z., Shiver J.W., Volkin D.B. Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines. J. Pharm. Sci. 2004, 93:1924-1939.
39. Fearon D.T. Seeking wisdom in innate immunity. Nature 1997, 388:323-324.
40. Fearon K., Marshall J.D., Abbate C., Subramanian S., Yee P., Gregorio J., Teshima G., Ott G., Tuck S., Van Nest G., Coffman R.L. A minimal human immunostimulatory CpG motif that potently induces IFN-gamma and IFN-alpha production. Eur. J. Immunol. 2003, 33:2114-2122.
41. Fehr T., Skrastina D., Pumpens P, Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA 1998, 95:9477-9481.
42. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F., Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173:3148-3154.
43. Ghosh M.K., Deriaud E., Saron M.F., Lo-Man R., Henry T., Jiao X., Roy P., Leclerc C. Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences. Vaccine 2002, 20:1369-1377.
44. Giannelli V., Fontana M.R., Giuliani M.M., Guangcai D., Rappuoli R., Pizza M. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect. Immun. 1997, 65:331-334.
45. Gilbert S.C. Vaccine Adjuvants: Preparation Methods and Research Protocols 2000, Vol. 42:197-210. Humana Press, Totowa, NJ. D. O'Hagan (Ed.).
46. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., Hill A.V. A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnol. 1997, 15:1280-1284.
47. Giuliani M.M., Del Giudice G., Giannelli V., Dougan G., Douce G., Rappuoli R., Pizza M. Mucosal adjuvanticity and immunogenicity of Ltr72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 1998, 187:1123-1132.
48. Glaueri A.M., Dingle J.T., Lucy J.A. Action of saponins on biological membranes. Nature 1962, 196:953.
49. Goldberg J., Shrikant P., Mescher M.F. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J. Immunol. 2003, 170:228-235.
50. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today 1990, 11:89-97.
51. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv. Drug Del. Rev. 1998, 32:155-172.
52. Gupta R.K., Chang A.C., Griffin P., Rivera R., Siber G.R. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 1996, 14:1412-1416.
53. Haining W.N., Anderson D.G., Little S.R., von Bergwelt-Baildon M.S., Cardoso A.A., Alves P., Kosmatopoulos K., Nadler L.M., Langer R., Kohane D.S. Ph-triggered microparticles for peptide vaccination. J. Immunol. 2004, 173:2578-2585.
54. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., Zahaf T., Innis B., Naud P., De Carvalho N.S., Roteli-Martins C.M., Teixeira J., Blatter M.M., Korn A.P., Quint W., Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a Randomised controlled trial. Lancet 2004, 364:1757-1765.
55. Heath A.W. Cytokines as immunological adjuvants. Pharm. Biotechnol. 1995, 6:645-658.
56. Hedley M.L., Curley J., Urban R. Microspheres Containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nature Med. 1998, 4:365-368.
57. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., Akira S., Moingeon P. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
58. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 Myd88-dependent signaling pathway. Nature Immunol. 2002, 3:196-200.
59. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21:S89-S95.
60. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunol. 2004, 5:987-995.
61. Jakobsen H., Schulz D., Pizza M., Rappuoli R., Jonsdottir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections. Infect. Immun. 1999, 67:5892-5897.
62. Janeway C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harbor Symp. Quant. Biol. 1989, 54:1-13. (Pt 1).
63. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., Bachi T., Storni T., Jennings G., Pumpens P., Renner W.A., Bachmann M.F. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20:3104-3112.
64. Jiang W., Gupta R.K., Deshpande M.C., Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 2005, 57:391-410.
65. Johansen P., Gander B., Merkle H.P., Sesardic D. Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol. 2000, 18:203-211.
66. O.L.Johnson, Cleland J.L., Lee H.J., Charnis M., Duenas E., Jaworowicz W., Shepard D., Shahzamani A., Jones A.J., Putney S.D. A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med. 1996, 2:795-799.
67. Jones D.H., McBride B.W., Thornton C., O'Hagan D.T., Robinson A., Farrar G.H. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from b. pertussis respiratory infection. Infect. Immun. 1996, 64:489-494.
68. Jones D.H., Corris S., McDonald S., Clegg J.C., Farrar G.H. Poly(d,l-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15:814-817.
69. Jung T., Kamm W., Breitenbach A., Klebe G., Kissel T. Loading of tetanus toxoid to biodegradable nanoparticles from branched poly(sulfobutyl-polyvinyl alcohol)-g-(lactide-co-glycolide) nanoparticles by protein adsorption: a mechanistic study. Pharm. Res. 2002, 19:1105-1113.
70. Kanke M., Sniecinski I., DeLuca P.P. Interaction of microspheres with blood constituents: I. Uptake of polystyrene spheres by monocytes and granulocytes and effect on immune responsiveness of lymphocytes. J. Parenter. Sci. Technol. 1983, 37:210-217.
71. Katz D.E., DeLorimier A.J., Wolf M.K., Hall E.R., Cassels F.J., van Hamont J.E., Newcomer R.L., Davachi M.A., Taylor D.N., McQueen C.E. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (Etec) Cs6 antigen. Vaccine 2003, 21:341-346.
72. Kazzaz J., Neidleman J., Singh M., Ott G., O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant P55 Gag from HIV-1. J. Control. Release 2000, 67:347-356.
73. Kende M., Yan C., Hewetson J., Frick M.A., Rill W.L., Tammariello R. Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 2002, 20:1681-1691.
74. Kensil C.R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13:1-55.
75. Klavinskis L.S., Bergmeier L.A., Gao L., Mitchell E., Ward R.G., Layton G., Brookes R., Meyers N.J., Lehner T. Mucosal or targeted lymph node immunization of macaques with a particulate Sivp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J. Immunol. 1996, 157:2521-2527.
76. Klencke B., Matijevic M., Urban R.G., Lathey J.L., Hedley M.L., Berry M., Thatcher J., Weinberg V., Wilson J., Darragh T., Jay N., Da Costa M., Palefsky J.M. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of Zyc101. Clin. Cancer Res. 2002, 8:1028-1037.
77. Kovacsovics-Bankowski M., Clark K., Benacerraf B., Rock K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA 1993, 90:4942-4946.
78. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:6546-6549.
79. Lambert J.S., Keefer M., Mulligan M.J., Schwartz D., Mestecky J., Weinhold K., Smith C., Hsieh R., Moldoveanu Z., Fast P., Forrest B., Koff W. A phase I safety and immunogenicity trial of Ubi microparticulate monovalent HIV-1 Mn oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001, 19:3033-3042.
80. Levine M.M., Dougan G. Optimism over vaccines administered via mucosal surfaces. Lancet 1998, 351:1375-1376.
81. Little S.R., Lynn D.M., Ge Q., Anderson D.G., Puram S.V., Chen J., Eisen H.N., Langer R. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc. Natl. Acad. Sci. USA 2004, 101:9534-9539. Epub 2004 Jun 21.
82. Lo D., Hilbush B., Mah S., Brayden D., Byrne D., Higgins L., O'Mahony D.J. Catching target receptors for drug and vaccine delivery using Toga gene expression profiling. Adv. Drug Deliv. Rev. 2002, 54:1213-1223.
83. Luby T.M., Cole G., Baker L., Kornher J.S., Ramstedt U., Hedley M.L. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable t cell responses to the tumor-associated antigen cytochrome P450 1b1. Clin. Immunol. 2004, 112:45-53.
84. Luo Y., O'Hagan D., Zhou H., Singh M., Ulmer J., Reisfeld R.A., James Primus F., Xiang R. Plasmid DNA encoding human carcinoembryonic antigen (Cea) adsorbed onto cationic microparticles induces protective immunity against colon cancer in Cea-transgenic mice. Vaccine 2003, 21:1938-1947.
85. Lutsiak M.E., Robinson D.R., Coester C., Kwon G.S., Samuel J. Analysis of poly(d,l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 2002, 19:1480-1487.
86. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 1994, 81:661-667.
87. Marchetti M., Rossi M., Giannelli V., Giuliani M.M., Pizza M., Censini S., Covacci A., Massari P., Pagliaccia C., Manetti R., Telford J.L., Douce G., Dougan G., Rappuoli R., Ghiara P. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 1998, 16:33-37.
88. Marshall J.D., Higgins D., Abbate C., Yee P., Teshima G., Ott G., dela Cruz T., Passmore D., Fearon K.L., Tuck S., Van Nest G. Polymyxin B enhances Iss-mediated immune responses across multiple species. Cell. Immunol. 2004, 229:93-105.
89. Martin S.J., Vyakarnam A., Cheingsong-Popov R., Callow D., Jones K.L., Senior J.M., Adams S.E., Kingsman A.J., Matear P., Gotch F.M. Immunization of human HIV-seronegative volunteers with recombinant P17/P24:Ty virus-like particles elicits HIV-1 P24-specific cellular and humoral immune responses. AIDS 1993, 7:1315-1323.
90. Marx P.A., Compans R.W., Gettie A., Staas J.K., Gilley R.M., Mulligan M.J., Yamschikov G.V., Chen D., Eldridge J.H. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993, 260:1323-1327.
91. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos C.A., Vijayaraghavan K., Montgomery S., Bassett M., Morrell C. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997, 386:410-414.
92. McGee J.P., Davis S.S., O'Hagan D. The immunogenicity of a model protein entrapped in poly (lactide-co-glycolide) microparticles prepared by a novel phase separation technique. J. Control. Release 1994, 31:55-60.
93. Medzhitov R., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997, 91:295-298.
94. Men Y., Thomasin C., Merkle H.P., Gander B., Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine 1995, 13:683-689.
95. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 1991, 147:1759-1764.
96. Mollenkopf H.J., Dietrich G., Fensterle J., Grode L., Diehl K.D., Knapp B., Singh M., O'Hagan D.T., Ulmer J.B., Kaufmann S.H. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 2004, 22:2690-2695.
97. Moore A., McGuirk P., Adams S., Jones W.C., McGee J.P., O'Hagan D.T., Mills K.H. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific Cd8+cytotoxic t lymphocytes and Cd4+ Th1 cells. Vaccine 1995, 13:1741-1749.
98. Mutant Heat-Labile Enterotoxins as Adjuvants for CTL Induction 2000, Humana Press, Totowa, NJ. J.A. Neidleman, G. Ott, D. O'Hagan (Eds.).
99. Newman K.D., Elamanchili P., Kwon G.S., Samuel J. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater. Res. 2002, 60:480-486.
100. Newman M.J., Balusubramanian M., Todd C.W. Development of adjuvant-active nonionic block copolymers. Adv. Drug Del. Rev. 1998, 32:199-223.
101. Nixon D.F., Hioe C., Chen P.D., Bian Z., Kuebler P., Li M.L., Qiu H., Li X.M., Singh M., Richardson J., Mcgee P., Zamb T., Koff W., Wang C.Y., O'Hagan D. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996, 14:1523-1530.
102. O'Hagan D. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 1998, 34:305-320.
103. O'Hagan D., Rappuoli R. Novel approaches to vaccine delivery. Pharm. Res. 2004, 9:1519-1530.
104. O'Hagan D., Goldbeck C., Ugozzoli M., Ott G., Burke R.L. Intranasal immunization with recombinant Gd2 reduces disease severity and mortality following genital challenge with herpes simple virus type 2 in inguinea pigs. Vaccine 1999, 17:2229-2236.
105. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chem M., Otten G.R., Ulmer J.B. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines. J. Virol. 2001, 75:9037-9043.
106. O'Hagan D.T. HIV and mucosal immunity. Lancet 1991, 337:1289.
107. O'Hagan D.T. Novel Delivery Systems for Oral Vaccines 1994, 175-205. CRC Press, Boca Raton, FL. D.T. O'Hagan (Ed.).
108. O'Hagan D.T. The intestinal uptake of particles and the implications for drug and antigen delivery. J. Anat. 1996, 189(Pt 3):477-482.
109. O'Hagan D.T., Rappuoli R. The safety of vaccines. Drug Discov. Today 2004, 9:846-854.
110. O'Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccines and adjuvants. Nature Rev. Drug Discov. 2003, 2:727-735.
111. O'Hagan D.T., Jeffery H., Roberts M.J., McGee J.P., Davis S.S. Controlled release microparticles for vaccine development. Vaccine 1991, 9:768-771.
112. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., Davis S.S., Challacombe S.J. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991, 73:239-242.
113. O'Hagan D.T., Jeffery H., Davis S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11:965-969.
114. O'Hagan D.T., Jeffery H., Davis S.S. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. Vaccine 1993, 11:965-969.
115. O'Hagan D.T., Singh M., Gupta R.K. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Del. Rev. 1998, 32:225-246.
116. O'Hagan D.T., Ugozzoli M., Barackman J., Singh M., Kazzaz J., Higgins K., VanCott T.C., Ott G. Micropaticles in Mf59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1. Vaccine 2000, 18:1793-1801.
117. O'Hagan D.T., Singh M., Kazzaz J., Ugozzoli M., Briones M., Donnelly J., Ott G. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV P55 Gag antigen. Vaccine 2002, 20:3389-3398.
118. O'Hagan D.T., Singh M., Dong C., Ugozzoli M., Berger K., Glazer E., Selby M., Wininger M., Ng P., Crawford K., Paliard X., Coates S., Houghton M. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine 2004, 23:672-680.
119. O'Hagan D.T., Singh M., Ulmer J.B. Microparticles for the delivery of DNA vaccines. Immunol. Rev. 2004, 199:191-200.
120. Okada H., Toguchi H. Biodegradable Microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1995, 12:1-99.
121. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., Van Nest G. Vaccine Design: The Subunit and Adjuvant Approach 1995, 277-296. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
122. Ott G., Singh M., Kazzaz J., Briones M., Soenawan E., Ugozzoli M., O'Hagan D.T. A cationic submicron emulsion (Mf59/ Dotap) is an effective delivery system for DNA vaccines. J. Control. Release 2002, 79:1-5.
123. Otten G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., Kazzaz J., Lian Y., Singh M., Ugozzoli M., Montefiori D., Lewis M., Driver D.A., Dubensky T.W., Polo J., Donnelly J., O'Hagan D.T., Barnett S., Ulmer J. Enhanced potency of plasmid DNA/PLG microparticle HIV vaccines in rhesus macaques using a prime-boost regimen with recombinant proteins. J. Virol. 2005, 79:8189-8200.
124. Otten G.R., Schaefer M., Greer C., Calderon-Cacia M., Coit D., Kazzaz J., Medina-Selby A., Selby M., Singh M., Ugozzoli M., zur Megede J., Barnett S., O'Hagan D., Donnelly J., Ulmer J.B. Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles. J. Virol. 2003, 77:6087-6092.
125. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., Andrianov A.K., Roberts B.E. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16:92-98.
126. Peppoloni S., Ruggiero P., Contorni M., Morandi M., Pizza M., Rappuoli R., Podda A., Del Giudice G. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2003, 2:285-293.
127. Pettit D.K., Lawter J.R., Huang W.J., Pankey S.C., Nightlinger N.S., Lynch D.H., Schuh J.A., Morrissey P.J., Gombotz W.R. Characterization of poly(glycolide-co-d,l-lactide)/poly(d,l-lactide) microspheres for controlled release of GM-CSF. Pharm. Res. 1997, 14:1422-1430.
128. Polakos N.K., Drane D., Cox J., Ng P., Selby M.J., Chien D., O'Hagan D.T., Houghton M., Paliard X. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical iscom vaccine. J. Immunol. 2001, 166:3589-3598.
129. Preis I., Langer R.S. A single-step immunization by sustained antigen release. J. Immunol. Methods 1979, 28:193-197.
130. Puri N., Sinko P.J. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres: II. In vivo investigation. J. Control. Release 2000, 69:69-80.
131. Putney S.D., Burke P.A. Improving protein therapeutics with sustained-release formulations [published erratum appears in Nature Biotechnol. (1998), 16, 478]. Nature Biotechnol. 1998, 16:153-157.
132. Ramon G. Sur la toxine et surranatoxine diphtheriques. Ann. Inst. Pasteur 1924, 38:1.
133. Randolph G.J., Inaba K., Robbiani D.F., Steinman R.M., Muller W.A. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999, 11:753-761.
134. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today 1999, 20:493-500.
135. Relyveld E.H., Bizzini B., Gupta R.K. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 1998, 16:1016-1023.
136. Riedl P., Stober D., Oehninger C., Melber K., Reimann J., Schirmbeck R. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 2002, 168:4951-4959.
137. Ryan E.J., McNeela E., Murphy G.A., Stewart H., O'Hagan D., Pizza M., Rappuoli R., Mills K.H. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect. Immun. 1999, 67:6270-6280.
138. Sasiak A.B., Bolgiano B., Crane D.T., Hockley D.J., Corbel M.J., Sesardic D. Comparison of in vitro and in vivo methods to study stability of PLGA microencapsulated tetanus toxoid vaccines. Vaccine 2001, 19:694-705.
139. Schirmbeck R., Bohm W., Ando K., Chisari F.V., Reimann J. Nucleic-acid vaccination primes hepatitis-B virus surface antigen-specific cytotoxic T-lymphocytes in nonresponder mice. J. Virol. 1995, 69:5929-5934.
140. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., Becker M., Sinden R., Smith G.L., Hill A.V. Enhanced immunogenicity for Cd8+T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 1998, 4:397-402.
141. Schwendeman S.P., Costantino H.R., Gupta R.K., Siber G.R., Klibanov A.M., Langer R. Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. Proc. Natl. Acad. Sci. USA 1995, 92:11234-11238.
142. Seder R.A., Gurunathan S. DNA vaccines: designer vaccines for the 21st century. N. Engl. J. Med 1999, 341:277-278.
143. Seo J.Y., Seong S.Y., Ahn B.Y., Kwon I.C., Chung H., Jeong S.Y. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres. Infect. Immun. 2002, 70:1143-1149.
144. Shahin R., Leef M., Eldridge J., Hudson M., Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(d,l-lactide-co-glycolide) microspheres. Infect. Immun. 1995, 63:1195-1200.
145. Shi L., Caulfield M.J., Chern R.T., Wilson R.A., Sanyal G., Volkin D.B. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci. 2002, 91:1019-1035.
146. Shi Y., Rock K.L. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur. J. Immunol. 2002, 32:155-162.
147. Shi Y., HogenEsch H., Regnier F.E., Hem S.L. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 2001, 19:1747-1752.
148. Simmons C.P., Mastroeni P., Fowler R., Ghaem-maghami M., Lycke N., Pizza M., Rappuoli R., Dougan G. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 1999, 163:6502-6510.
149. Singh M., O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm. Res. 2002, 19:715-728.
150. Singh M., Li X.M., McGee J.P., Zamb T., Koff W., Wang C.Y., O'Hagan D.T. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine 1997, 15:475-481.
151. Singh M., Li X.M., Wang H., McGee J.P., Zamb T., Koff W., Wang C.Y., O'Hagan D.T. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 1997, 65:1716-1721.
152. Singh M., Carlson J.R., Briones M., Ugozzoli M., Kazzaz J., Barackman J., Ott G., O'Hagan D. A comparison of biodegradable microparticles and Mf59 as systemic adjuvants for recombinant Gd from HSV-2. Vaccine 1998, 16:1822-1827.
153. Singh M., Li X.M., Wang H., McGee J.P., Zamb T., Koff W., Wang C.Y., O'Hagan D.T. Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. Vaccine 1998, 16:346-352.
154. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. Proc. Natl. Acad. Sci. USA 2000, 97:811-816.
155. Singh M., Ott G., Kazzaz J., Ugozzoli M., Briones M., Donnelly J., O'Hagan D.T. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm. Res. 2001, 18:1476-1479.
156. Singh M., Vajdy M., Gardner J., Briones M., O'Hagan D. Mucosal immunization with HIV-1 Gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 2002, 20:594-602.
157. Singh M., Ugozzoli M., Briones M., Kazzaz J., Soenawan E., O'Hagan D.T. The effect of Ctab concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharm. Res. 2003, 20:247-251.
158. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., O'Hagan D. Adsorption of a novel recombinant glycoprotein from HIV (Env Gp120dv2sf162) to anionic PLG microparticles retains the structural integrity of the protein, while encapsulation in PLG microparticles does not. Pharm. Res. 2004, 21:2148-2152.
159. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., Pizza M., Rappouli R., O'Hagan D.T. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci. 2004, 93:273-282.
160. Srivastava I.K., Liu M.A. Gene vaccines. Ann. Inter. Med. 2003, 138:550-559.
161. Storni T., Ruedl C., Renner W.A., Bachman M.F. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J. Immunol. 2003, 171:795-801.
162. Storni T., Ruedl C., Schwarz K., Schwendener R.A., Renner W.A., Bachmann M.F. Nonmethylated Cg motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol. 2004, 172:1777-1785.
163. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408:605-609.
164. Tabata Y., Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol. 1987, 39:698-704.
165. Tabata Y., Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res. 1987, 22:837-858.
166. Tabata Y., Ikada Y. Phagocytosis of polymer microspheres by macrophages. Adv. Polym. Sci. 1990, 94:107-141.
167. Tacket C.O., Reid R.H., Boedeker E.C., Losonsky G., Nataro J.P., Bhagat H., Edelman R. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli Cfa/II encapsulated in biodegradable microspheres. Vaccine 1994, 12:1270-1274.
168. Tamber H., Johansen P., Merkle H.P., Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57:357-376.
169. Thiele L., Merkle H.P., Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm. Res. 2003, 20:221-228.
170. Tinsley-Bown A.M., Fretwell R., Dowsett A.B., Davis S.L., Farrar G.H. Formulation of poly(d,l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J. Control. Release 2000, 66:229-241.
171. Tokunaga T., Yamamoto H., Shimada S., Abe H., Fukuda T., Fujisawa Y., Furutani Y., Yano O., Kataoka T., Sudo T. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG: I. Isolation, physicochemical characterization, and antitumor activity. J. Nat. Cancer Inst. 1984, 72:955-962.
172. Tseng J., Komisar J.L., Trout R.N., Hunt R.E., Chen J.Y., Johnson A.J., Pitt L., Ruble D.L. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres. Infect. Immun. 1995, 63:2880-2885.
173. Ugozzoli M., O'Hagan D.T., Ott G.S. Intranasal immunization of mice with herpes simplex virus type 2 recombinant Gd2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 1998, 93:563-571.
174. Ugozzoli M., Santos G., Donnelly J., O'Hagan D.T. Potency of a genetically detoxified mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (Ltk63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J. Infect. Dis. 2001, 183:351-354.
175. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 2001, 69:1151-1159.
176. Ulrich J.T. Vaccine Adjuvants: Preparation Methods and Research Protocols 2000, 273-282. Humana Press, Totowa, NJ. O. D.T. (Ed.).
177. Vajdy M., O'Hagan D.T. Microparticles for intranasal immunization. Adv. Drug Deliv. Rev. 2001, 51:127-141.
178. Vajdy M., Singh M., Ugozzoli M., Briones M., Soenawan E., Cuadra L., Kazzaz J., Ruggiero P., Peppoloni S., Norelli F., del Giudice G., O'Hagan D. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations. Immunology 2003, 110:86-94.
179. Vajdy M., Singh M., Kazzaz J., Soenawan E., Ugozzoli M., Zhou F., Srivastava I., Bin Q., Barnett S., Donnelly J., Luciw P., Lourdes L., Montefiori D., O'Hagan D. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intra-nasal and parenteral immunizations. AIDS Res. Hum. Retroviruses 2004, 20:1269-1281.
180. Vajdy M., Srivastava I., Polo J., Donnelly J., O'Hagan D., Singh M. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol. Cell Biol. 2004, 82:617-627.
181. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982, 298:347-350.
182. Vogel F.R., Powell M.F. Vaccine Design: The Subunit and Adjuvant Approach 1995, 141-228. Plenum Press, New York. M.F. Powell, M.J. Newman (Eds.).
183. Vordermeier H.M., Coombes A.G., Jenkins P., McGee J.P., O'Hagan D.T., Davis S.S., Singh M. Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine 1995, 13:1576-1582.
184. Walter E., Moelling K., Pavlovic J., Merkle H.P. Microencapsulation of DNA using poly(d,l-lactide-co-glycolide): stability issues and release characteristics. J. Control. Reelease 1999, 61:361-374.
185. Wang C., Ge Q., Ting D., Nguyen D., Shen H.R., Chen J., Eisen H.N., Heller J., Langer R., Putnam D. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nature Mater 2004, 3:190-196. Epub 2004 Feb 15.
186. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., Jones T.R., Hobart P., Margalith M., Ng J., Weiss W.R., Sedegah M., de Taisne C., Norman J.A., Hoffman S.L. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
187. Wheeler A.W., Marshall J.S., Ulrich J.T. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 2001, 126:135-139.
188. Whittum-Hudson J.A., An L.L., Saltzman W.M., Prendergast R.A., MacDonald A.B. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nature Med. 1996, 2:1116-1121.
189. Xie H. CpG oligodeoxynucleotides adsorbed onto polylactide-coglycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect. Immun. 2005, 73:828-833.
190. Xing X., Liu V., Xia W., Stephens L.C., Huang L., Lopez-Berestein G., Hung M.C. Safety studies of the intraperitoneal injection of Ela-liposome complex in mice. Gene Ther. 1997, 4:238-243.
191. Zinkernagel R.M., Ehl S., Aichele P., Oehen S., Kundig T., Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 1997, 156:199-209.